Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial.
Friedlander M, Mileshkin L, Lombard J, Frentzas S, Gao B, Wilson M, Meniawy T, Baron-Hay S, Briscoe K, McCarthy N, Fountzilas C, Cervantes A, Ge R, Wu J, Spira A. Friedlander M, et al. Among authors: fountzilas c. Br J Cancer. 2023 Sep;129(5):797-810. doi: 10.1038/s41416-023-02349-0. Epub 2023 Jul 20. Br J Cancer. 2023. PMID: 37474720 Free PMC article. Clinical Trial.
Multicenter phase 2 trial of nintedanib in advanced nonpancreatic neuroendocrine tumors.
Iyer RV, Konda B, Fountzilas C, Mukherjee S, Owen D, Attwood K, Wang C, Maguire O, Minderman H, Suffren SA, Hicks K, Wilton J, Bies R, Casucci D, Reidy-Lagunes D, Shah M. Iyer RV, et al. Among authors: fountzilas c. Cancer. 2020 Aug 15;126(16):3689-3697. doi: 10.1002/cncr.32994. Epub 2020 Jun 11. Cancer. 2020. PMID: 32525561 Free PMC article. Clinical Trial.
A phase II study of REOLYSIN® (pelareorep) in combination with carboplatin and paclitaxel for patients with advanced malignant melanoma.
Mahalingam D, Fountzilas C, Moseley J, Noronha N, Tran H, Chakrabarty R, Selvaggi G, Coffey M, Thompson B, Sarantopoulos J. Mahalingam D, et al. Among authors: fountzilas c. Cancer Chemother Pharmacol. 2017 Apr;79(4):697-703. doi: 10.1007/s00280-017-3260-6. Epub 2017 Mar 13. Cancer Chemother Pharmacol. 2017. PMID: 28289863 Clinical Trial.
Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates.
Malhotra U, Mukherjee S, Fountzilas C, Boland P, Miller A, Patnaik S, Attwood K, Yendamuri S, Adjei A, Kannisto E, Opyrchal M, Bushunow P, Loud P, Iyer R, Khushalani N. Malhotra U, et al. Among authors: fountzilas c. Mol Cancer Ther. 2020 Jan;19(1):304-311. doi: 10.1158/1535-7163.MCT-19-0240. Epub 2019 Oct 1. Mol Cancer Ther. 2020. PMID: 31575653 Clinical Trial.
A dose regimen-finding study to evaluate the safety, tolerability, pharmacokinetics, and activity of oratecan in subjects with advanced malignancies.
Boland PM, Fountzilas C, Fakih M, Opyrchal M, Diamond JR, Corr B, Ma WW, Redman M, Chan WK, Wang H, Kramer D, Kwan R, Cutler D, Zhi J, Jimeno A. Boland PM, et al. Among authors: fountzilas c. Cancer Chemother Pharmacol. 2022 Aug;90(2):175-187. doi: 10.1007/s00280-022-04453-z. Epub 2022 Jul 29. Cancer Chemother Pharmacol. 2022. PMID: 35904620 Clinical Trial.
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
Mahalingam D, Wilkinson GA, Eng KH, Fields P, Raber P, Moseley JL, Cheetham K, Coffey M, Nuovo G, Kalinski P, Zhang B, Arora SP, Fountzilas C. Mahalingam D, et al. Among authors: fountzilas c. Clin Cancer Res. 2020 Jan 1;26(1):71-81. doi: 10.1158/1078-0432.CCR-19-2078. Epub 2019 Nov 6. Clin Cancer Res. 2020. PMID: 31694832 Free PMC article. Clinical Trial.
57 results